Next Thursday the Alliance for Regenerative Medicine (ARM), GE Healthcare and the Cell Therapy Catapult in partnership with BIA will hold the 2nd Annual European Advanced Therapies Investor Day, an event to provide institutional, corporate and private investors with unique insight into the investment case for advanced therapies-based treatments and tools.

BIA member company ReNeuron is a leading, clinical-stage business, developing novel stem cell therapies targeting areas of significant unmet or poorly met medical need. In this week’s video ReNeuron’s Chief Financial Officer Michael Hunt talks to Edison Investment Research about the company’s cell-based technology platforms and the potential ‘clinical data catalysts’ for investors to watch out for over the next 12-18 months.

Edison_ReNeuron

Do you have a video you would like the sector to see? Contact us.